Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
2.000
+0.050 (2.55%)
Nov 21, 2024, 1:24 PM EST - Market open
Sangamo Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for SGMO stock have an average target of 7.00, with a low estimate of 2.00 and a high estimate of 10. The average target predicts an increase of 250.00% from the current stock price of 2.00.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for SGMO stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 0 | 0 | 0 | 1 |
| Hold | 3 | 3 | 3 | 3 | 3 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +400.00% | Nov 14, 2024 |
| Barclays | Barclays | Buy Maintains $3 → $9 | Buy | Maintains | $3 → $9 | +350.00% | Nov 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $10 | Strong Buy | Maintains | $5 → $10 | +400.00% | Nov 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +150.00% | Oct 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +150.00% | Oct 22, 2024 |
Financial Forecast
Revenue This Year
49.02M
from 176.23M
Decreased by -72.19%
Revenue Next Year
84.21M
from 49.02M
Increased by 71.79%
EPS This Year
-0.49
from -1.48
EPS Next Year
-0.22
from -0.49
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 153.3M | 212.1M | 193.8M | ||
| Avg | 49.0M | 84.2M | 107.2M | ||
| Low | 980,000 | 19.6M | 24.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -13.0% | 332.7% | 130.2% | ||
| Avg | -72.2% | 71.8% | 27.2% | ||
| Low | -99.4% | -60.0% | -71.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.02 | 0.19 | 0.11 | ||
| Avg | -0.49 | -0.22 | -0.15 | ||
| Low | -0.69 | -0.58 | -0.56 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.